https://www.selleckchem.com/products/680c91.html
Interleukin (IL)-17A level was found to be increased in the nasal mucosa of the co-exposure group compared with that in the HDM-exposed group. The levels of IL-4, IL-13, interferon-γ, IL-25, IL-33, and TSLP expression showed no difference between the groups with and without DEP treatment. Increased expression of IL-17A in the nasal mucosa may contribute to DEP-mediated exacerbation of AR in HDM-sensitized murine AR model.People receiving COVID-19 vaccines may subsequently markedly increase their previously suppressed exposure risk. A sim
Like
Comment
Share
